Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072904 · ClinicalTrials.gov registry record · Phase 3
Diabetes Therapy to Improve BMI and Lung Function in CF
A Phase 3 study of Diabetes Mellitus and Cystic Fibrosis, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 7
- Study locations
NCT00072904 is a Phase 3 study of Diabetes Mellitus and Cystic Fibrosis that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 108 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00072904, a Phase 3 study of Diabetes Mellitus and Cystic Fibrosis, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 7
- Study locations
Study Summary
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Repaglinide
- DRUG Insulin Asparte
Study Locations (7)
California
- Stanford University - Palo Alto
Massachusetts
- Baystate Medical Center - Springfield
Minnesota
- University of Minnesota Medical Center - Minneapolis
Pennsylvania
- Children's Hospital of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Utah
- University of Utah - Salt Lake City
Ontario
- St. Michael's Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2001-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072904
The ClinicalTrials.gov registry entry for NCT00072904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Repaglinide is the first listed.
NCT00072904 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00072904 about?
NCT00072904 is a clinical study titled "Diabetes Therapy to Improve BMI and Lung Function in CF". To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic f...
What is the current status of trial NCT00072904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2001-06. Estimated completion is 2007-12.
What conditions does trial NCT00072904 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Cystic Fibrosis.
What interventions are being tested in trial NCT00072904?
The interventions under investigation include: Repaglinide (DRUG), Insulin Asparte (DRUG).
Who is sponsoring clinical trial NCT00072904?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00072904 being conducted?
This trial has 7 study locations across California, Massachusetts, Minnesota, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.